Becton Dickinson & Co - BDX STOCK NEWS

BD (NYSE: BDX) has received FDA 510(k) clearance and launched the Phasix™ ST Umbilical Hernia Patch, marking a significant innovation in hernia repair as the first fully absorbable hernia patch specifically designed for umbilical hernias. The patch is made from Poly-4-hydroxybutyrate (P4HB), a biologically-derived material, combined with a Sepra® Technology hydrogel barrier.

The product maintains the same surgical technique as traditional permanent mesh patches, featuring a pocket and strap design for easy placement. It builds on the success of the Ventralex™ ST Hernia Patch family, which has over two million implants globally. Survey data shows 60% of patients prefer non-permanent mesh options, with 70% of surgeons willing to accommodate these preferences.

The Phasix™ family of products has demonstrated success with over 385,000 implants globally, supported by more than 85 clinical publications studying over 4,000 patients. The new patch is available in three sizes to accommodate various umbilical soft tissue defects.

BD (NYSE: BDX) has launched HemoSphere Alta™, an advanced hemodynamic monitoring platform featuring AI-driven algorithms to help clinicians manage blood pressure and flow during critical procedures. The platform introduces the first-of-its-kind Cerebral Autoregulation Index (CAI), which monitors brain blood flow stability using ForeSight IQ™ and Acumen IQ™ sensors.

The system includes the Acumen Hypotension Prediction Index (HPI)™ software, proven to reduce hypotension severity in multicenter studies. Notable features include a 15" high-resolution touchscreen, split-screen views, voice and gesture commands, and minimal pop-ups for improved user experience.

This launch represents the first major product from BD's Advanced Patient Monitoring business since its acquisition, advancing BD's position in smart, connected care technologies.

BD (NYSE: BDX), a leading global medical technology company, has scheduled a financial results announcement for its second quarter of fiscal year 2025. The company will host an audio webcast on May 1, 2025, at 8 a.m. ET to discuss the quarterly performance ended March 31, 2025.

The presentation will include summary financial information, operational updates, and strategic insights. Investors can access the webcast through BD's investor relations website, where a replay will be available afterward. Prior to the call, BD will release detailed financial information and presentation materials on their investor website.

BD (NYSE: BDX), a leading global medical technology company, has been recognized on Fortune's 2025 list of America's Most Innovative Companies, placing in the top 25% overall. The recognition was based on a comprehensive survey of over 40,000 U.S. employees and 2,500 industry experts.

The evaluation focused on three key categories:

• Product innovation: Introduction of new products and improvement of existing ones, including patent portfolio
• Process innovation: Development of new technologies and production processes
• Innovation culture: Fostering entrepreneurship and employee creativity

Tom Polen, chairman, CEO and president of BD, emphasized the company's commitment to innovation as one of the world's largest medical device manufacturers, serving billions of patients globally through their BD Excellence culture of continuous improvement.

BD (NYSE: BDX) has appointed Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, currently serves as executive chairman of RTX and brings over 30 years of executive experience. This appointment aligns with BD's transformation strategy, particularly as the company prepares for the planned separation of its Diagnostic Solutions and Biosciences business.

Hayes' extensive background includes CEO and senior leadership roles in finance, corporate strategy, and business development. At United Technologies (UTC), he served as CEO from 2014 and chairman from 2016, playing a key role in the 2020 merger that formed RTX. He previously served as UTC's CFO from 2008 to 2014.

Hayes is the fourth independent director added to BD's board since 2021, demonstrating the company's commitment to board refreshment and strong corporate governance.

BD (NYSE: BDX) has initiated a significant clinical trial for its GalaFLEX LITE™ Scaffold in breast implant revision surgery. The first patient has been treated in an IDE clinical trial aimed at obtaining FDA Premarket Approval for reducing capsular contracture recurrence.

The STANCE study will evaluate the scaffold's effectiveness in decreasing capsular contracture, a common complication affecting 10-20% of breast implant surgeries. The trial targets enrollment of at least 250 patients across 40 investigative sites, with patients randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care.

The scaffold, made from P4HB (a bioabsorbable polymer), is designed to provide immediate strength during healing. Five medical centers are currently enrolling patients, marking BD's advancement in biomaterial science for tissue reconstruction.

BD (NYSE: BDX), a leading global medical technology company, has announced its participation in two upcoming healthcare investor conferences. The company will present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day on February 27, 2025, at 8:45 a.m. Eastern Time, and at the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 8:30 a.m. Eastern Time.

Investors and interested parties can access live webcasts of both presentations through the BD investor relations website at investors.bd.com. Recordings of the presentations will be made available for replay on the same platform after the events conclude.

BD (NYSE: BDX) announced plans to separate its Biosciences and Diagnostic Solutions business from the core company to enhance strategic focus and value creation. The separation will create two distinct entities:

1. 'New BD': A pure-play medical technology company with projected FY2024 revenue of $17.8 billion, focusing on four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. It will target a $70+ billion addressable market with 90% recurring revenue.

2. Biosciences and Diagnostic Solutions: Expected to generate $3.4 billion in FY2024 revenue, targeting a $22+ billion market with 80% recurring revenue and ~30% adjusted EBITDA margins. This entity will focus on immunology, cancer research solutions, and diagnostic services.

The company plans to announce specific separation details by the end of fiscal 2025, with completion targeted for fiscal 2026. The transaction structure remains under consideration, with options including a Reverse Morris Trust, sale, or spin-off.

BD (NYSE: BDX) reported strong Q1 fiscal 2025 results, with revenue reaching $5.2 billion, representing a 9.8% increase as reported, 9.6% currency-neutral, and 3.9% organic growth. The company demonstrated robust financial performance with GAAP diluted EPS of $1.04 (up 8.3%) and adjusted diluted EPS of $3.43 (up 28.0%).

The company has completed $750 million in share repurchases to date in FY25 and has increased its FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency impacts. BD also announced plans to separate its Biosciences and Diagnostic Solutions businesses to enhance value creation and focus on market-specific growth strategies.